TTY Biopharm（4105）株式概要TTYバイオファーム社は、その子会社とともに、台湾および国際的な医薬品および化学薬品の開発・販売に従事している。 詳細4105 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績5/6財務の健全性6/6配当金5/6報酬当社が推定した公正価値より72.5%で取引されている 過去1年間で収益は9.5%増加しました リスク分析不安定な配当実績 すべてのリスクチェックを見る4105 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,122 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA487,122 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$77.3014.3% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture010b2016201920222025202620282031Revenue NT$10.2bEarnings NT$2.6bAdvancedSet Fair ValueView all narrativesTTY Biopharm Company Limited 競合他社Synmosa BiopharmaSymbol: TPEX:4114Market cap: NT$16.1bYungShin Global HoldingSymbol: TWSE:3705Market cap: NT$14.4bCenter LaboratoriesSymbol: TPEX:4123Market cap: NT$26.2bStandard Chemical & PharmaceuticalSymbol: TWSE:1720Market cap: NT$11.1b価格と性能株価の高値、安値、推移の概要TTY Biopharm過去の株価現在の株価NT$77.3052週高値NT$87.0052週安値NT$71.60ベータ0.111ヶ月の変化-1.40%3ヶ月変化1.71%1年変化1.71%3年間の変化3.20%5年間の変化-0.26%IPOからの変化1,177.53%最新ニュースReported Earnings • Aug 06Second quarter 2026 earnings released: EPS: NT$1.63 (vs NT$1.15 in 2Q 2025)Second quarter 2026 results: EPS: NT$1.63 (up from NT$1.15 in 2Q 2025). Revenue: NT$1.65b (up 9.2% from 2Q 2025). Net income: NT$406.4m (up 43% from 2Q 2025). Profit margin: 25% (up from 19% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Reported Earnings • May 07First quarter 2026 earnings released: EPS: NT$1.00 (vs NT$1.57 in 1Q 2025)First quarter 2026 results: EPS: NT$1.00. Revenue: NT$1.52b (up 4.2% from 1Q 2025). Net income: NT$443.1m (up 13% from 1Q 2025). Profit margin: 29% (up from 27% in 1Q 2025).Declared Dividend • Mar 11Dividend increased to NT$4.50Dividend of NT$4.50 is 7.1% higher than last year. Ex-date: 26th March 2026 Payment date: 27th April 2026 Dividend yield will be 5.5%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (65% cash payout ratio). The dividend has increased by an average of 5.3% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Mar 10+ 1 more updateTTY Biopharm Company Limited, Annual General Meeting, May 28, 2026TTY Biopharm Company Limited, Annual General Meeting, May 28, 2026. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city TaiwanPrice Target Changed • Nov 27Price target increased by 13% to NT$88.00Up from NT$78.00, the current price target is an average from 2 analysts. New target price is 7.8% above last closing price of NT$81.60. Stock is up 9.2% over the past year. The company is forecast to post earnings per share of NT$6.77 for next year compared to NT$5.83 last year.Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$2.33 (vs NT$1.50 in 3Q 2024)Third quarter 2025 results: EPS: NT$2.33 (up from NT$1.50 in 3Q 2024). Revenue: NT$1.82b (up 19% from 3Q 2024). Net income: NT$580.2m (up 56% from 3Q 2024). Profit margin: 32% (up from 24% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.最新情報をもっと見るRecent updatesReported Earnings • Aug 06Second quarter 2026 earnings released: EPS: NT$1.63 (vs NT$1.15 in 2Q 2025)Second quarter 2026 results: EPS: NT$1.63 (up from NT$1.15 in 2Q 2025). Revenue: NT$1.65b (up 9.2% from 2Q 2025). Net income: NT$406.4m (up 43% from 2Q 2025). Profit margin: 25% (up from 19% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Reported Earnings • May 07First quarter 2026 earnings released: EPS: NT$1.00 (vs NT$1.57 in 1Q 2025)First quarter 2026 results: EPS: NT$1.00. Revenue: NT$1.52b (up 4.2% from 1Q 2025). Net income: NT$443.1m (up 13% from 1Q 2025). Profit margin: 29% (up from 27% in 1Q 2025).Declared Dividend • Mar 11Dividend increased to NT$4.50Dividend of NT$4.50 is 7.1% higher than last year. Ex-date: 26th March 2026 Payment date: 27th April 2026 Dividend yield will be 5.5%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (65% cash payout ratio). The dividend has increased by an average of 5.3% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Mar 10+ 1 more updateTTY Biopharm Company Limited, Annual General Meeting, May 28, 2026TTY Biopharm Company Limited, Annual General Meeting, May 28, 2026. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city TaiwanPrice Target Changed • Nov 27Price target increased by 13% to NT$88.00Up from NT$78.00, the current price target is an average from 2 analysts. New target price is 7.8% above last closing price of NT$81.60. Stock is up 9.2% over the past year. The company is forecast to post earnings per share of NT$6.77 for next year compared to NT$5.83 last year.Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$2.33 (vs NT$1.50 in 3Q 2024)Third quarter 2025 results: EPS: NT$2.33 (up from NT$1.50 in 3Q 2024). Revenue: NT$1.82b (up 19% from 3Q 2024). Net income: NT$580.2m (up 56% from 3Q 2024). Profit margin: 32% (up from 24% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Reported Earnings • Sep 04Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: NT$1.15 (up from NT$1.05 in 2Q 2024). Revenue: NT$1.51b (up 10.0% from 2Q 2024). Net income: NT$284.7m (up 8.8% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 5.6%. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Reported Earnings • Aug 06Second quarter 2025 earnings released: EPS: NT$1.14 (vs NT$1.05 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.14 (up from NT$1.05 in 2Q 2024). Revenue: NT$1.51b (up 10.0% from 2Q 2024). Net income: NT$284.7m (up 8.8% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • May 30TTY Biopharm Company Limited Approves Cash Dividend for the Year 2024TTY Biopharm Company Limited at its AGM held on May 29, 2025, approved year 2024 profit distribution, TWD 4.2 cash dividend per share.Reported Earnings • May 15First quarter 2025 earnings: EPS exceeds analyst expectationsFirst quarter 2025 results: EPS: NT$1.57 (up from NT$1.13 in 1Q 2024). Revenue: NT$1.46b (up 14% from 1Q 2024). Net income: NT$391.1m (up 39% from 1Q 2024). Profit margin: 27% (up from 22% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 15%. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • May 07TTY Biopharm Company Limited to Report Q1, 2025 Results on May 14, 2025TTY Biopharm Company Limited announced that they will report Q1, 2025 results on May 14, 2025Upcoming Dividend • Mar 20Upcoming dividend of NT$4.20 per shareEligible shareholders must have bought the stock before 27 March 2025. Payment date: 25 April 2025. Payout ratio is a comfortable 72% and the cash payout ratio is 86%. Trailing yield: 5.2%. Within top quartile of Taiwanese dividend payers (4.6%). Higher than average of industry peers (2.5%).Declared Dividend • Feb 27Dividend increased to NT$4.20Dividend of NT$4.20 is 20% higher than last year. Ex-date: 27th March 2025 Payment date: 25th April 2025 Dividend yield will be 5.3%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (78% earnings payout ratio) and cash flows (86% cash payout ratio). The dividend has increased by an average of 6.4% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 14% to shift the payout ratio to a potentially unsustainable range, which is more than the 2.0% EPS decline seen over the last 5 years.お知らせ • Feb 26+ 1 more updateTTY Biopharm Company Limited, Annual General Meeting, May 29, 2025TTY Biopharm Company Limited, Annual General Meeting, May 29, 2025. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city Taiwanお知らせ • Feb 18TTY Biopharm Company Limited to Report Q4, 2024 Results on Feb 25, 2025TTY Biopharm Company Limited announced that they will report Q4, 2024 results on Feb 25, 2025Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: NT$1.50 (vs NT$1.51 in 3Q 2023)Third quarter 2024 results: EPS: NT$1.50 (down from NT$1.51 in 3Q 2023). Revenue: NT$1.53b (up 7.0% from 3Q 2023). Net income: NT$372.6m (down 1.0% from 3Q 2023). Profit margin: 24% (down from 26% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 06TTY Biopharm Company Limited to Report Q3, 2024 Results on Nov 13, 2024TTY Biopharm Company Limited announced that they will report Q3, 2024 results on Nov 13, 2024Reported Earnings • Aug 10Second quarter 2024 earnings released: EPS: NT$1.05 (vs NT$1.24 in 2Q 2023)Second quarter 2024 results: EPS: NT$1.05 (down from NT$1.24 in 2Q 2023). Revenue: NT$1.37b (up 9.0% from 2Q 2023). Net income: NT$261.7m (down 15% from 2Q 2023). Profit margin: 19% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Aug 02TTY Biopharm Company Limited to Report Q2, 2024 Results on Aug 08, 2024TTY Biopharm Company Limited announced that they will report Q2, 2024 results on Aug 08, 2024Buy Or Sell Opportunity • Jun 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 3.5% to NT$77.00. The fair value is estimated to be NT$96.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 15%.お知らせ • May 31+ 1 more updateTTY Biopharm Company Limited Approves Cash Dividend for the Year 2023TTY Biopharm Company Limited at its 2024 Annual General Meeting held on May 30, 2024, approved cash dividend of TWD 3.5 per share for the year 2023.Price Target Changed • May 25Price target decreased by 9.3% to NT$78.00Down from NT$86.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$77.40. Stock is up 3.1% over the past year. The company is forecast to post earnings per share of NT$4.90 for next year compared to NT$4.54 last year.Buy Or Sell Opportunity • May 16Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 2.4% to NT$77.30. The fair value is estimated to be NT$96.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 5.5% in a year. Earnings are forecast to grow by 22% in the next year.Reported Earnings • May 11First quarter 2024 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2024 results: EPS: NT$1.13 (up from NT$0.96 in 1Q 2023). Revenue: NT$1.27b (up 9.2% from 1Q 2023). Net income: NT$280.8m (up 18% from 1Q 2023). Profit margin: 22% (up from 21% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 9.7%. Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 36% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • May 01TTY Biopharm Company Limited to Report Q1, 2024 Results on May 07, 2024TTY Biopharm Company Limited announced that they will report Q1, 2024 results on May 07, 2024Upcoming Dividend • Mar 21Upcoming dividend of NT$3.50 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 26 April 2024. Payout ratio and cash payout ratio are on the higher end at 77% and 86% respectively. Trailing yield: 4.3%. Lower than top quartile of Taiwanese dividend payers (4.7%). Higher than average of industry peers (1.7%).Reported Earnings • Mar 15Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: NT$4.53 (up from NT$4.40 in FY 2022). Revenue: NT$5.51b (up 8.8% from FY 2022). Net income: NT$1.13b (up 3.1% from FY 2022). Profit margin: 21% (down from 22% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 5.2%. Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Declared Dividend • Mar 10Dividend increased to NT$3.50Dividend of NT$3.50 is 2.9% higher than last year. Ex-date: 28th March 2024 Payment date: 26th April 2024 Dividend yield will be 4.4%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (72% earnings payout ratio) but not covered by cash flows (111% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 33% over the next 2 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Mar 09+ 1 more updateTTY Biopharm Company Limited Announces Change of CFO and Financial OfficerTTY Biopharm Company Limited announced the change of CFO and financial officer. Name, title, and resume of the previous position holder: Chang, Guo-Jiang, CFO and financial officer, corporate governance officer. Name, title, and resume of the new position holder: Chiang, Yung-Min, chief auditor. Education: Soochow University, Master of Laws In-Service Program in Financial and Economic Law; Soochow University, Master Program in Accounting. Experience: Synmosa, Senior Manager of Finance Department; Shin Kong Mitsukoshi, Investment Management Manager; The Landis Taipei, Group senior financial accounting associate. Effective date is March 8, 2024.お知らせ • Jan 31+ 1 more updateTTY Biopharm Company Limited, Annual General Meeting, May 30, 2024TTY Biopharm Company Limited, Annual General Meeting, May 30, 2024. Location: No.1, Jingmao 2nd Rd., Nangang District Taipei City Taiwan Agenda: To consider year 2023 business report; to consider report on audit committee reviewed financial statements for year 2023; to consider report on communication between members of the audit committee and internal chief auditor; to consider report on employee and directors remuneration for year 2023; to consider report on distribution of cash dividends from profits for year 2023; to consider report on related party transactions for year 2023; and to consider other matters.Reported Earnings • Nov 05Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2023 results: EPS: NT$1.51 (up from NT$1.36 in 3Q 2022). Revenue: NT$1.43b (up 8.0% from 3Q 2022). Net income: NT$376.3m (up 11% from 3Q 2022). Profit margin: 26% (in line with 3Q 2022). Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 5.9%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 59% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Price Target Changed • Oct 27Price target increased by 10% to NT$86.00Up from NT$78.00, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of NT$83.00. Stock is up 12% over the past year. The company is forecast to post earnings per share of NT$5.24 for next year compared to NT$4.40 last year.New Risk • Sep 19New major risk - Revenue and earnings growthEarnings have declined by 9.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.1% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Reported Earnings • Aug 11Second quarter 2023 earnings: EPS exceeds analyst expectationsSecond quarter 2023 results: EPS: NT$1.24 (up from NT$1.14 in 2Q 2022). Revenue: NT$1.26b (up 8.2% from 2Q 2022). Net income: NT$308.7m (up 8.6% from 2Q 2022). Profit margin: 25% (in line with 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.5%. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Price Target Changed • Jun 29Price target increased by 14% to NT$84.50Up from NT$74.00, the current price target is an average from 2 analysts. New target price is 8.2% above last closing price of NT$78.10. Stock is up 8.8% over the past year. The company is forecast to post earnings per share of NT$4.79 for next year compared to NT$4.40 last year.お知らせ • May 25TTY Biopharm Company Limited Announces Decision Rendered by the Supreme Court for Validity of the Risperidone Development Agreement Between the Company and Center Laboratories, IncTTY Biopharm Company Limited announced decision rendered by the Supreme Court for validity of the Risperidone Development Agreement between the Company and Center Laboratories Inc. Reference/Case number of relevant documents of the legal matter is 2023 Tai Shang Zi No. 765. Details of occurrence (including the matter under dispute): On August 20, 2010, TTY Biopharm Company Limited signed the Risperidone Development Agreement with Center Laboratories Inc. in which Center Lab engaged TTY for developing Risperidone product. TTY claimed that this agreement is invalid and Center Lab therefore filed a civil confirmation lawsuit against TTY. Handling procedure: Previously Taiwan High Court dismissed the claim of Center Lab and ruled that the above-mentioned agreement is invalid and the contractual relationship is not existing. Center Lab appealed to the Supreme Court and the Supreme Court had reversed the High Court's judgment and remanded the case to Taiwan High Court. Countermeasures and improvement status: TTY will discuss with legal counsels regarding the follow-up measures for this case.Buying Opportunity • Mar 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 4.3%. The fair value is estimated to be NT$99.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.2% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 10% in 2 years. Earnings is forecast to grow by 8.0% in the next 2 years.Upcoming Dividend • Mar 23Upcoming dividend of NT$3.40 per share at 4.3% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 05 May 2023. Payout ratio is on the higher end at 77%, however this is supported by cash flows. Trailing yield: 4.3%. Lower than top quartile of Taiwanese dividend payers (6.0%). Higher than average of industry peers (1.6%).Reported Earnings • Mar 15Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: NT$4.40 (up from NT$3.35 in FY 2021). Revenue: NT$5.06b (up 12% from FY 2021). Net income: NT$1.09b (up 32% from FY 2021). Profit margin: 22% (up from 18% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 3.1%. Revenue is forecast to grow 4.9% p.a. on average during the next 2 years, compared to a 47% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 9% per year.Price Target Changed • Jan 08Price target decreased to NT$71.50Down from NT$79.50, the current price target is an average from 2 analysts. New target price is 13% below last closing price of NT$81.90. Stock is up 20% over the past year. The company is forecast to post earnings per share of NT$4.67 for next year compared to NT$3.35 last year.Price Target Changed • Nov 23Price target increased to NT$79.50Up from NT$73.00, the current price target is an average from 2 analysts. New target price is 5.8% below last closing price of NT$84.40. Stock is up 22% over the past year. The company is forecast to post earnings per share of NT$4.62 for next year compared to NT$3.35 last year.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. 3 independent directors (5 non-independent directors). Independent Director Ming-Ling Hsueh was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 06Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: NT$1.36 (up from NT$1.02 in 3Q 2021). Revenue: NT$1.33b (up 25% from 3Q 2021). Net income: NT$338.0m (up 33% from 3Q 2021). Profit margin: 26% (up from 24% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year.お知らせ • Nov 05TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022TTY Biopharm Company Limited announced that Kao, Jung-Liang will be replaced with Chiang, Yung-Min, Senior Manager of Finance Department of Synmosa Biopharma Corporation, as internal audit officer, effective November 7, 2022.Reported Earnings • Aug 07Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: NT$1.14 (up from NT$0.13 in 2Q 2021). Revenue: NT$1.17b (up 12% from 2Q 2021). Net income: NT$284.2m (up NT$252.3m from 2Q 2021). Profit margin: 24% (up from 3.1% in 2Q 2021). The increase in margin was primarily driven by lower expenses. Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 4.6%. Over the next year, revenue is forecast to grow 2.5%, compared to a 39% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 4% per year.Upcoming Dividend • Jul 12Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 19 July 2022. Payment date: 15 August 2022. Payout ratio and cash payout ratio are on the higher end at 87% and 86% respectively. Trailing yield: 4.0%. Lower than top quartile of Taiwanese dividend payers (6.7%). Higher than average of industry peers (2.8%).お知らせ • Jul 02TTY Biopharm Company Limited Announces Dividend Distribution, Payable on August 15, 2022TTY Biopharm Company Limited announced dividend distribution of Cash dividend TWD 745,949,877, TWD 3 cash dividend per share. Ex-rights (Ex-dividend) date is July 19, 2022. Last date before book closure is July 20, 2022. Book closure starting date is July 21, 2022. Book closure ending date is July 25, 2022. Ex-rights (Ex-dividend) record date is July 25, 2022. Payment date of cash dividend distribution is August 15, 2022.お知らせ • May 27TTY Biopharm Company Limited Announces Cash Dividend for the Year 2021TTY Biopharm Company Limited announced that at its AGM held on 26 May 2022, the company has approved cash dividend of TWD 3 per share for the year 2021.Price Target Changed • Apr 27Price target decreased to NT$73.00Down from NT$80.00, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of NT$73.80. Stock is up 3.5% over the past year. The company is forecast to post earnings per share of NT$4.23 for next year compared to NT$3.35 last year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. 3 independent directors (6 non-independent directors). Independent Director Ming-Ling Hsueh was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 01TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration CommitteeTTY Biopharm Company Limited announced the resignation of Chou,Te-Yu as member of remuneration committee. Any other matters that need to be specified: Due to personal career planning, CHOU,TE-YU resigned the committee member of Remuneration committee as from March 31, 2022.Price Target Changed • Mar 17Price target decreased to NT$73.67Down from NT$80.00, the current price target is an average from 4 analysts. New target price is 9.0% above last closing price of NT$67.60. Stock is down 2.6% over the past year. The company is forecast to post earnings per share of NT$4.26 for next year compared to NT$3.35 last year.Reported Earnings • Mar 11Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: EPS: NT$3.35 (down from NT$3.72 in FY 2020). Revenue: NT$4.54b (up 7.4% from FY 2020). Net income: NT$831.9m (down 10.0% from FY 2020). Profit margin: 18% (down from 22% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 4.1%, compared to a 20% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Major Estimate Revision • Dec 18Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate increased from NT$3.05 to NT$3.38. Revenue forecast steady at NT$4.47b. Net income forecast to grow 32% next year vs 34% growth forecast for Pharmaceuticals industry in Taiwan. Consensus price target of NT$80.60 unchanged from last update. Share price was steady at NT$69.00 over the past week.Reported Earnings • Nov 07Third quarter 2021 earnings released: EPS NT$1.02 (vs NT$0.90 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$1.06b (up 3.5% from 3Q 2020). Net income: NT$253.4m (up 14% from 3Q 2020). Profit margin: 24% (up from 22% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Sep 07Upcoming dividend of NT$4.00 per shareEligible shareholders must have bought the stock before 14 September 2021. Payment date: 15 October 2021. Trailing yield: 5.0%. Lower than top quartile of Taiwanese dividend payers (5.2%). Higher than average of industry peers (2.3%).Price Target Changed • Aug 19Price target increased to NT$80.00Up from NT$74.20, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of NT$77.50. Stock is up 17% over the past year.Major Estimate Revision • Aug 18Consensus EPS estimates fall to NT$2.87The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from NT$4.71b to NT$4.40b. EPS estimate also fell from NT$4.05 to NT$2.87. Net income forecast to grow 17% next year vs 16% growth forecast for Pharmaceuticals industry in Taiwan. Consensus price target of NT$79.33 unchanged from last update. Share price was steady at NT$78.90 over the past week.Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS NT$0.13 (vs NT$0.75 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: NT$1.04b (up 16% from 2Q 2020). Net income: NT$31.9m (down 83% from 2Q 2020). Profit margin: 3.1% (down from 21% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Price Target Changed • May 23Price target increased to NT$80.20Up from NT$74.20, the current price target is an average from 5 analysts. New target price is 6.1% below last closing price of NT$85.40. Stock is up 15% over the past year.Price Target Changed • May 17Price target increased to NT$80.20Up from NT$74.60, the current price target is an average from 4 analysts. New target price is 9.4% below last closing price of NT$88.50. Stock is up 18% over the past year.Valuation Update With 7 Day Price Move • May 12Investor sentiment improved over the past weekAfter last week's 22% share price gain to NT$88.80, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 22x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 4.9% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at NT$106 per share.Reported Earnings • May 07First quarter 2021 earnings released: EPS NT$0.82 (vs NT$1.02 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$964.1m (down 12% from 1Q 2020). Net income: NT$203.1m (down 20% from 1Q 2020). Profit margin: 21% (down from 23% in 1Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.分析記事 • Apr 02Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt ResponsiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Mar 21+ 1 more updateTty Biopharm Company Limited Proposes Dividend for the Period January 1, 2020 to December 31, 2020TTY Biopharm Company Limited at its board meeting held on March 19, 2021 proposed dividend for the period January 1, 2020 to December 31, 2020. The dividend proposed the total amount of cash dividends to shareholders TWD of 994,599,836. Per value of common stock to be TWD 10.Reported Earnings • Mar 20Full year 2020 earnings released: EPS NT$3.72 (vs NT$3.62 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: NT$4.22b (down 5.5% from FY 2019). Net income: NT$924.2m (up 2.7% from FY 2019). Profit margin: 22% (up from 20% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.分析記事 • Mar 15Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?Today we will run through one way of estimating the intrinsic value of TTY Biopharm Company Limited ( GTSM:4105 ) by...分析記事 • Feb 25Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?Could TTY Biopharm Company Limited ( GTSM:4105 ) be an attractive dividend share to own for the long haul? Investors...Price Target Changed • Feb 19Price target lowered to NT$73.50Down from NT$79.14, the current price target is an average from 5 analysts. The new target price is 18% above the current share price of NT$62.30. As of last close, the stock is down 21% over the past year.分析記事 • Feb 07TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?With its stock down 11% over the past three months, it is easy to disregard TTY Biopharm (GTSM:4105). However, stock...お知らせ • Feb 06TTY Biopharm Company Limited, Annual General Meeting, Jun 09, 2021TTY Biopharm Company Limited, Annual General Meeting, Jun 09, 2021. Location: Building A, 2F., No. 19-10, Sanchong Rd., Nangang Dist. International Convention Center of Nangang Software Park Taipei City Taiwan Agenda: To consider the year 2020 business report; to consider the audit committee's review report on the year 2020 financial statements; to consider the report on employee and directors remuneration in year 2020; to consider the year 2020 business report and financial statements; to consider the year 2020 profit distribution; to consider the revising the policy of procedures for election of directors; to consider the release of non-competition restriction on new directors and its representatives; and to consider the other matters.Is New 90 Day High Low • Jan 29New 90-day low: NT$61.40The company is down 19% from its price of NT$76.20 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is NT$118 per share.分析記事 • Jan 19TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts SubstantiallyThe latest analyst coverage could presage a bad day for TTY Biopharm Company Limited ( GTSM:4105 ), with the analysts...Is New 90 Day High Low • Jan 11New 90-day low: NT$68.10The company is down 19% from its price of NT$84.00 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is NT$251 per share.分析記事 • Jan 10What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...分析記事 • Dec 15TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Nov 25How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?Dividend paying stocks like TTY Biopharm Company Limited (GTSM:4105) tend to be popular with investors, and for good...お知らせ • Nov 21TTY Biopharm Company Limited Announces Executive Changes, with Effect from January 20, 2021TTY Biopharm Company Limited replaced Tsai Shi-Hua with Hu Yu-Fang as research and development officer with effect from January 20, 2021.Analyst Estimate Surprise Post Earnings • Nov 04Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 9.2%. Over the next year, revenue is forecast to grow 40%, compared to a 68% growth forecast for the Pharmaceuticals industry in Taiwan.Reported Earnings • Nov 04Third quarter 2020 earnings released: EPS NT$0.89The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$1.02b (down 11% from 3Q 2019). Net income: NT$222.4m (down 30% from 3Q 2019). Profit margin: 22% (down from 28% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Oct 15Market bids up stock over the past weekAfter last week's 25% share price gain to NT$84.30, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 21.3x. This compares to an average P/E of 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders over the past three years are 5.3%.Is New 90 Day High Low • Oct 15New 90-day high: NT$84.30The company is up 15% from its price of NT$73.20 on 17 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is NT$75.00 per share.Major Estimate Revision • Oct 14Analysts lower revenue estimates to NT$4.14bThe 2020 consensus revenue estimate decreased from NT$4.64b. Earning per share (EPS) estimate was also lowered from NT$4.57 to NT$3.79 for the same period. Net income is expected to grow by 40% next year compared to 44% growth forecast for the Pharmaceuticals industry in Taiwan. The consensus price target increased from NT$78.66 to NT$80.17. Share price is up 13% to NT$76.40 over the past week.Is New 90 Day High Low • Sep 24New 90-day low: NT$66.20The company is down 13% from its price of NT$76.20 on 24 June 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is NT$75.71 per share.株主還元4105TW PharmaceuticalsTW 市場7D0.9%1.3%4.0%1Y1.7%-14.7%84.6%株主還元を見る業界別リターン: 4105過去 1 年間で-14.7 % の収益を上げたTW Pharmaceuticals業界を上回りました。リターン対市場: 4105は、過去 1 年間で84.6 % のリターンを上げたTW市場を下回りました。価格変動Is 4105's price volatile compared to industry and market?4105 volatility4105 Average Weekly Movement2.1%Pharmaceuticals Industry Average Movement5.3%Market Average Movement6.5%10% most volatile stocks in TW Market12.1%10% least volatile stocks in TW Market2.7%安定した株価: 4105 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 4105の 週次ボラティリティ ( 2% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1960n/an/awww.tty.com.twTTY Biopharm Company Limitedは子会社とともに、台湾および海外で医薬品および化学薬品の開発・販売を行っている。同社はオンコロジー事業部、集中治療事業部、ヘルスケア事業部、輸出・CDMO事業部、その他事業部の各セグメントを通じて事業を展開している。リポドックス、ロンサーフ、UFUR、TS-1、ペクセダ、ジェミス、オキサリップ、イリノ、エピシン、タイネン、アナゾ、フォリーナ、タド、アンダソン、アイビック、アサディン、レアブド、ペインキル、メジェスト、エピシル、オトリル、ゾボニック、ヨンデリス、ペマジールの名称で抗がん剤や補助治療薬を提供している。感染症・インフルエンザ治療薬としては、Brosym、Colimycin、Cubicin、Lipo-AB、Agrippal、Cepiro、Flusine、Maxtam、Metacin、Flucelvaxを提供している。さらに、消化器系、骨粗鬆症、代謝を対象としたヘルスケア関連医薬品をAlgitab、Alginos、Alginos Fresh、Bio-Cal Plus、Sulfinの名称で提供している。さらに、機能性食品の販売、輸出入貿易、投資活動も行っている。同社は1960年に設立され、台湾の台北に本社を置いている。もっと見るTTY Biopharm Company Limited 基礎のまとめTTY Biopharm の収益と売上を時価総額と比較するとどうか。4105 基礎統計学時価総額NT$19.22b収益（TTM）NT$1.73b売上高(TTM)NT$6.65b11.1xPER（株価収益率2.9xP/Sレシオ4105 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4105 損益計算書（TTM）収益NT$6.65b売上原価NT$2.82b売上総利益NT$3.83bその他の費用NT$2.10b収益NT$1.73b直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）6.97グロス・マージン57.57%純利益率26.04%有利子負債／自己資本比率27.0%4105 の長期的なパフォーマンスは？過去の実績と比較を見る配当金5.8%現在の配当利回り69%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/12 18:59終値2026/08/12 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TTY Biopharm Company Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Christine WangDaiwa Securities Co. Ltd.Caren HuangJ.P. MorganYu-Ying YangKGI Securities Co. Ltd.4 その他のアナリストを表示
Reported Earnings • Aug 06Second quarter 2026 earnings released: EPS: NT$1.63 (vs NT$1.15 in 2Q 2025)Second quarter 2026 results: EPS: NT$1.63 (up from NT$1.15 in 2Q 2025). Revenue: NT$1.65b (up 9.2% from 2Q 2025). Net income: NT$406.4m (up 43% from 2Q 2025). Profit margin: 25% (up from 19% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Reported Earnings • May 07First quarter 2026 earnings released: EPS: NT$1.00 (vs NT$1.57 in 1Q 2025)First quarter 2026 results: EPS: NT$1.00. Revenue: NT$1.52b (up 4.2% from 1Q 2025). Net income: NT$443.1m (up 13% from 1Q 2025). Profit margin: 29% (up from 27% in 1Q 2025).
Declared Dividend • Mar 11Dividend increased to NT$4.50Dividend of NT$4.50 is 7.1% higher than last year. Ex-date: 26th March 2026 Payment date: 27th April 2026 Dividend yield will be 5.5%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (65% cash payout ratio). The dividend has increased by an average of 5.3% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Mar 10+ 1 more updateTTY Biopharm Company Limited, Annual General Meeting, May 28, 2026TTY Biopharm Company Limited, Annual General Meeting, May 28, 2026. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city Taiwan
Price Target Changed • Nov 27Price target increased by 13% to NT$88.00Up from NT$78.00, the current price target is an average from 2 analysts. New target price is 7.8% above last closing price of NT$81.60. Stock is up 9.2% over the past year. The company is forecast to post earnings per share of NT$6.77 for next year compared to NT$5.83 last year.
Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$2.33 (vs NT$1.50 in 3Q 2024)Third quarter 2025 results: EPS: NT$2.33 (up from NT$1.50 in 3Q 2024). Revenue: NT$1.82b (up 19% from 3Q 2024). Net income: NT$580.2m (up 56% from 3Q 2024). Profit margin: 32% (up from 24% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 06Second quarter 2026 earnings released: EPS: NT$1.63 (vs NT$1.15 in 2Q 2025)Second quarter 2026 results: EPS: NT$1.63 (up from NT$1.15 in 2Q 2025). Revenue: NT$1.65b (up 9.2% from 2Q 2025). Net income: NT$406.4m (up 43% from 2Q 2025). Profit margin: 25% (up from 19% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Reported Earnings • May 07First quarter 2026 earnings released: EPS: NT$1.00 (vs NT$1.57 in 1Q 2025)First quarter 2026 results: EPS: NT$1.00. Revenue: NT$1.52b (up 4.2% from 1Q 2025). Net income: NT$443.1m (up 13% from 1Q 2025). Profit margin: 29% (up from 27% in 1Q 2025).
Declared Dividend • Mar 11Dividend increased to NT$4.50Dividend of NT$4.50 is 7.1% higher than last year. Ex-date: 26th March 2026 Payment date: 27th April 2026 Dividend yield will be 5.5%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (65% cash payout ratio). The dividend has increased by an average of 5.3% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Mar 10+ 1 more updateTTY Biopharm Company Limited, Annual General Meeting, May 28, 2026TTY Biopharm Company Limited, Annual General Meeting, May 28, 2026. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city Taiwan
Price Target Changed • Nov 27Price target increased by 13% to NT$88.00Up from NT$78.00, the current price target is an average from 2 analysts. New target price is 7.8% above last closing price of NT$81.60. Stock is up 9.2% over the past year. The company is forecast to post earnings per share of NT$6.77 for next year compared to NT$5.83 last year.
Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$2.33 (vs NT$1.50 in 3Q 2024)Third quarter 2025 results: EPS: NT$2.33 (up from NT$1.50 in 3Q 2024). Revenue: NT$1.82b (up 19% from 3Q 2024). Net income: NT$580.2m (up 56% from 3Q 2024). Profit margin: 32% (up from 24% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Sep 04Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: NT$1.15 (up from NT$1.05 in 2Q 2024). Revenue: NT$1.51b (up 10.0% from 2Q 2024). Net income: NT$284.7m (up 8.8% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 5.6%. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Reported Earnings • Aug 06Second quarter 2025 earnings released: EPS: NT$1.14 (vs NT$1.05 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.14 (up from NT$1.05 in 2Q 2024). Revenue: NT$1.51b (up 10.0% from 2Q 2024). Net income: NT$284.7m (up 8.8% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • May 30TTY Biopharm Company Limited Approves Cash Dividend for the Year 2024TTY Biopharm Company Limited at its AGM held on May 29, 2025, approved year 2024 profit distribution, TWD 4.2 cash dividend per share.
Reported Earnings • May 15First quarter 2025 earnings: EPS exceeds analyst expectationsFirst quarter 2025 results: EPS: NT$1.57 (up from NT$1.13 in 1Q 2024). Revenue: NT$1.46b (up 14% from 1Q 2024). Net income: NT$391.1m (up 39% from 1Q 2024). Profit margin: 27% (up from 22% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 15%. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • May 07TTY Biopharm Company Limited to Report Q1, 2025 Results on May 14, 2025TTY Biopharm Company Limited announced that they will report Q1, 2025 results on May 14, 2025
Upcoming Dividend • Mar 20Upcoming dividend of NT$4.20 per shareEligible shareholders must have bought the stock before 27 March 2025. Payment date: 25 April 2025. Payout ratio is a comfortable 72% and the cash payout ratio is 86%. Trailing yield: 5.2%. Within top quartile of Taiwanese dividend payers (4.6%). Higher than average of industry peers (2.5%).
Declared Dividend • Feb 27Dividend increased to NT$4.20Dividend of NT$4.20 is 20% higher than last year. Ex-date: 27th March 2025 Payment date: 25th April 2025 Dividend yield will be 5.3%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (78% earnings payout ratio) and cash flows (86% cash payout ratio). The dividend has increased by an average of 6.4% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 14% to shift the payout ratio to a potentially unsustainable range, which is more than the 2.0% EPS decline seen over the last 5 years.
お知らせ • Feb 26+ 1 more updateTTY Biopharm Company Limited, Annual General Meeting, May 29, 2025TTY Biopharm Company Limited, Annual General Meeting, May 29, 2025. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city Taiwan
お知らせ • Feb 18TTY Biopharm Company Limited to Report Q4, 2024 Results on Feb 25, 2025TTY Biopharm Company Limited announced that they will report Q4, 2024 results on Feb 25, 2025
Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: NT$1.50 (vs NT$1.51 in 3Q 2023)Third quarter 2024 results: EPS: NT$1.50 (down from NT$1.51 in 3Q 2023). Revenue: NT$1.53b (up 7.0% from 3Q 2023). Net income: NT$372.6m (down 1.0% from 3Q 2023). Profit margin: 24% (down from 26% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 06TTY Biopharm Company Limited to Report Q3, 2024 Results on Nov 13, 2024TTY Biopharm Company Limited announced that they will report Q3, 2024 results on Nov 13, 2024
Reported Earnings • Aug 10Second quarter 2024 earnings released: EPS: NT$1.05 (vs NT$1.24 in 2Q 2023)Second quarter 2024 results: EPS: NT$1.05 (down from NT$1.24 in 2Q 2023). Revenue: NT$1.37b (up 9.0% from 2Q 2023). Net income: NT$261.7m (down 15% from 2Q 2023). Profit margin: 19% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Aug 02TTY Biopharm Company Limited to Report Q2, 2024 Results on Aug 08, 2024TTY Biopharm Company Limited announced that they will report Q2, 2024 results on Aug 08, 2024
Buy Or Sell Opportunity • Jun 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 3.5% to NT$77.00. The fair value is estimated to be NT$96.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 15%.
お知らせ • May 31+ 1 more updateTTY Biopharm Company Limited Approves Cash Dividend for the Year 2023TTY Biopharm Company Limited at its 2024 Annual General Meeting held on May 30, 2024, approved cash dividend of TWD 3.5 per share for the year 2023.
Price Target Changed • May 25Price target decreased by 9.3% to NT$78.00Down from NT$86.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$77.40. Stock is up 3.1% over the past year. The company is forecast to post earnings per share of NT$4.90 for next year compared to NT$4.54 last year.
Buy Or Sell Opportunity • May 16Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 2.4% to NT$77.30. The fair value is estimated to be NT$96.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 5.5% in a year. Earnings are forecast to grow by 22% in the next year.
Reported Earnings • May 11First quarter 2024 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2024 results: EPS: NT$1.13 (up from NT$0.96 in 1Q 2023). Revenue: NT$1.27b (up 9.2% from 1Q 2023). Net income: NT$280.8m (up 18% from 1Q 2023). Profit margin: 22% (up from 21% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 9.7%. Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 36% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • May 01TTY Biopharm Company Limited to Report Q1, 2024 Results on May 07, 2024TTY Biopharm Company Limited announced that they will report Q1, 2024 results on May 07, 2024
Upcoming Dividend • Mar 21Upcoming dividend of NT$3.50 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 26 April 2024. Payout ratio and cash payout ratio are on the higher end at 77% and 86% respectively. Trailing yield: 4.3%. Lower than top quartile of Taiwanese dividend payers (4.7%). Higher than average of industry peers (1.7%).
Reported Earnings • Mar 15Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: NT$4.53 (up from NT$4.40 in FY 2022). Revenue: NT$5.51b (up 8.8% from FY 2022). Net income: NT$1.13b (up 3.1% from FY 2022). Profit margin: 21% (down from 22% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 5.2%. Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Declared Dividend • Mar 10Dividend increased to NT$3.50Dividend of NT$3.50 is 2.9% higher than last year. Ex-date: 28th March 2024 Payment date: 26th April 2024 Dividend yield will be 4.4%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (72% earnings payout ratio) but not covered by cash flows (111% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 33% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Mar 09+ 1 more updateTTY Biopharm Company Limited Announces Change of CFO and Financial OfficerTTY Biopharm Company Limited announced the change of CFO and financial officer. Name, title, and resume of the previous position holder: Chang, Guo-Jiang, CFO and financial officer, corporate governance officer. Name, title, and resume of the new position holder: Chiang, Yung-Min, chief auditor. Education: Soochow University, Master of Laws In-Service Program in Financial and Economic Law; Soochow University, Master Program in Accounting. Experience: Synmosa, Senior Manager of Finance Department; Shin Kong Mitsukoshi, Investment Management Manager; The Landis Taipei, Group senior financial accounting associate. Effective date is March 8, 2024.
お知らせ • Jan 31+ 1 more updateTTY Biopharm Company Limited, Annual General Meeting, May 30, 2024TTY Biopharm Company Limited, Annual General Meeting, May 30, 2024. Location: No.1, Jingmao 2nd Rd., Nangang District Taipei City Taiwan Agenda: To consider year 2023 business report; to consider report on audit committee reviewed financial statements for year 2023; to consider report on communication between members of the audit committee and internal chief auditor; to consider report on employee and directors remuneration for year 2023; to consider report on distribution of cash dividends from profits for year 2023; to consider report on related party transactions for year 2023; and to consider other matters.
Reported Earnings • Nov 05Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2023 results: EPS: NT$1.51 (up from NT$1.36 in 3Q 2022). Revenue: NT$1.43b (up 8.0% from 3Q 2022). Net income: NT$376.3m (up 11% from 3Q 2022). Profit margin: 26% (in line with 3Q 2022). Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 5.9%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 59% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Oct 27Price target increased by 10% to NT$86.00Up from NT$78.00, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of NT$83.00. Stock is up 12% over the past year. The company is forecast to post earnings per share of NT$5.24 for next year compared to NT$4.40 last year.
New Risk • Sep 19New major risk - Revenue and earnings growthEarnings have declined by 9.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.1% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Reported Earnings • Aug 11Second quarter 2023 earnings: EPS exceeds analyst expectationsSecond quarter 2023 results: EPS: NT$1.24 (up from NT$1.14 in 2Q 2022). Revenue: NT$1.26b (up 8.2% from 2Q 2022). Net income: NT$308.7m (up 8.6% from 2Q 2022). Profit margin: 25% (in line with 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.5%. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Jun 29Price target increased by 14% to NT$84.50Up from NT$74.00, the current price target is an average from 2 analysts. New target price is 8.2% above last closing price of NT$78.10. Stock is up 8.8% over the past year. The company is forecast to post earnings per share of NT$4.79 for next year compared to NT$4.40 last year.
お知らせ • May 25TTY Biopharm Company Limited Announces Decision Rendered by the Supreme Court for Validity of the Risperidone Development Agreement Between the Company and Center Laboratories, IncTTY Biopharm Company Limited announced decision rendered by the Supreme Court for validity of the Risperidone Development Agreement between the Company and Center Laboratories Inc. Reference/Case number of relevant documents of the legal matter is 2023 Tai Shang Zi No. 765. Details of occurrence (including the matter under dispute): On August 20, 2010, TTY Biopharm Company Limited signed the Risperidone Development Agreement with Center Laboratories Inc. in which Center Lab engaged TTY for developing Risperidone product. TTY claimed that this agreement is invalid and Center Lab therefore filed a civil confirmation lawsuit against TTY. Handling procedure: Previously Taiwan High Court dismissed the claim of Center Lab and ruled that the above-mentioned agreement is invalid and the contractual relationship is not existing. Center Lab appealed to the Supreme Court and the Supreme Court had reversed the High Court's judgment and remanded the case to Taiwan High Court. Countermeasures and improvement status: TTY will discuss with legal counsels regarding the follow-up measures for this case.
Buying Opportunity • Mar 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 4.3%. The fair value is estimated to be NT$99.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.2% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 10% in 2 years. Earnings is forecast to grow by 8.0% in the next 2 years.
Upcoming Dividend • Mar 23Upcoming dividend of NT$3.40 per share at 4.3% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 05 May 2023. Payout ratio is on the higher end at 77%, however this is supported by cash flows. Trailing yield: 4.3%. Lower than top quartile of Taiwanese dividend payers (6.0%). Higher than average of industry peers (1.6%).
Reported Earnings • Mar 15Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: NT$4.40 (up from NT$3.35 in FY 2021). Revenue: NT$5.06b (up 12% from FY 2021). Net income: NT$1.09b (up 32% from FY 2021). Profit margin: 22% (up from 18% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 3.1%. Revenue is forecast to grow 4.9% p.a. on average during the next 2 years, compared to a 47% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 9% per year.
Price Target Changed • Jan 08Price target decreased to NT$71.50Down from NT$79.50, the current price target is an average from 2 analysts. New target price is 13% below last closing price of NT$81.90. Stock is up 20% over the past year. The company is forecast to post earnings per share of NT$4.67 for next year compared to NT$3.35 last year.
Price Target Changed • Nov 23Price target increased to NT$79.50Up from NT$73.00, the current price target is an average from 2 analysts. New target price is 5.8% below last closing price of NT$84.40. Stock is up 22% over the past year. The company is forecast to post earnings per share of NT$4.62 for next year compared to NT$3.35 last year.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. 3 independent directors (5 non-independent directors). Independent Director Ming-Ling Hsueh was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 06Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: NT$1.36 (up from NT$1.02 in 3Q 2021). Revenue: NT$1.33b (up 25% from 3Q 2021). Net income: NT$338.0m (up 33% from 3Q 2021). Profit margin: 26% (up from 24% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year.
お知らせ • Nov 05TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022TTY Biopharm Company Limited announced that Kao, Jung-Liang will be replaced with Chiang, Yung-Min, Senior Manager of Finance Department of Synmosa Biopharma Corporation, as internal audit officer, effective November 7, 2022.
Reported Earnings • Aug 07Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: NT$1.14 (up from NT$0.13 in 2Q 2021). Revenue: NT$1.17b (up 12% from 2Q 2021). Net income: NT$284.2m (up NT$252.3m from 2Q 2021). Profit margin: 24% (up from 3.1% in 2Q 2021). The increase in margin was primarily driven by lower expenses. Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 4.6%. Over the next year, revenue is forecast to grow 2.5%, compared to a 39% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 4% per year.
Upcoming Dividend • Jul 12Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 19 July 2022. Payment date: 15 August 2022. Payout ratio and cash payout ratio are on the higher end at 87% and 86% respectively. Trailing yield: 4.0%. Lower than top quartile of Taiwanese dividend payers (6.7%). Higher than average of industry peers (2.8%).
お知らせ • Jul 02TTY Biopharm Company Limited Announces Dividend Distribution, Payable on August 15, 2022TTY Biopharm Company Limited announced dividend distribution of Cash dividend TWD 745,949,877, TWD 3 cash dividend per share. Ex-rights (Ex-dividend) date is July 19, 2022. Last date before book closure is July 20, 2022. Book closure starting date is July 21, 2022. Book closure ending date is July 25, 2022. Ex-rights (Ex-dividend) record date is July 25, 2022. Payment date of cash dividend distribution is August 15, 2022.
お知らせ • May 27TTY Biopharm Company Limited Announces Cash Dividend for the Year 2021TTY Biopharm Company Limited announced that at its AGM held on 26 May 2022, the company has approved cash dividend of TWD 3 per share for the year 2021.
Price Target Changed • Apr 27Price target decreased to NT$73.00Down from NT$80.00, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of NT$73.80. Stock is up 3.5% over the past year. The company is forecast to post earnings per share of NT$4.23 for next year compared to NT$3.35 last year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. 3 independent directors (6 non-independent directors). Independent Director Ming-Ling Hsueh was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 01TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration CommitteeTTY Biopharm Company Limited announced the resignation of Chou,Te-Yu as member of remuneration committee. Any other matters that need to be specified: Due to personal career planning, CHOU,TE-YU resigned the committee member of Remuneration committee as from March 31, 2022.
Price Target Changed • Mar 17Price target decreased to NT$73.67Down from NT$80.00, the current price target is an average from 4 analysts. New target price is 9.0% above last closing price of NT$67.60. Stock is down 2.6% over the past year. The company is forecast to post earnings per share of NT$4.26 for next year compared to NT$3.35 last year.
Reported Earnings • Mar 11Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: EPS: NT$3.35 (down from NT$3.72 in FY 2020). Revenue: NT$4.54b (up 7.4% from FY 2020). Net income: NT$831.9m (down 10.0% from FY 2020). Profit margin: 18% (down from 22% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 4.1%, compared to a 20% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Major Estimate Revision • Dec 18Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate increased from NT$3.05 to NT$3.38. Revenue forecast steady at NT$4.47b. Net income forecast to grow 32% next year vs 34% growth forecast for Pharmaceuticals industry in Taiwan. Consensus price target of NT$80.60 unchanged from last update. Share price was steady at NT$69.00 over the past week.
Reported Earnings • Nov 07Third quarter 2021 earnings released: EPS NT$1.02 (vs NT$0.90 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$1.06b (up 3.5% from 3Q 2020). Net income: NT$253.4m (up 14% from 3Q 2020). Profit margin: 24% (up from 22% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Sep 07Upcoming dividend of NT$4.00 per shareEligible shareholders must have bought the stock before 14 September 2021. Payment date: 15 October 2021. Trailing yield: 5.0%. Lower than top quartile of Taiwanese dividend payers (5.2%). Higher than average of industry peers (2.3%).
Price Target Changed • Aug 19Price target increased to NT$80.00Up from NT$74.20, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of NT$77.50. Stock is up 17% over the past year.
Major Estimate Revision • Aug 18Consensus EPS estimates fall to NT$2.87The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from NT$4.71b to NT$4.40b. EPS estimate also fell from NT$4.05 to NT$2.87. Net income forecast to grow 17% next year vs 16% growth forecast for Pharmaceuticals industry in Taiwan. Consensus price target of NT$79.33 unchanged from last update. Share price was steady at NT$78.90 over the past week.
Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS NT$0.13 (vs NT$0.75 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: NT$1.04b (up 16% from 2Q 2020). Net income: NT$31.9m (down 83% from 2Q 2020). Profit margin: 3.1% (down from 21% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Price Target Changed • May 23Price target increased to NT$80.20Up from NT$74.20, the current price target is an average from 5 analysts. New target price is 6.1% below last closing price of NT$85.40. Stock is up 15% over the past year.
Price Target Changed • May 17Price target increased to NT$80.20Up from NT$74.60, the current price target is an average from 4 analysts. New target price is 9.4% below last closing price of NT$88.50. Stock is up 18% over the past year.
Valuation Update With 7 Day Price Move • May 12Investor sentiment improved over the past weekAfter last week's 22% share price gain to NT$88.80, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 22x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 4.9% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at NT$106 per share.
Reported Earnings • May 07First quarter 2021 earnings released: EPS NT$0.82 (vs NT$1.02 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$964.1m (down 12% from 1Q 2020). Net income: NT$203.1m (down 20% from 1Q 2020). Profit margin: 21% (down from 23% in 1Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
分析記事 • Apr 02Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt ResponsiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Mar 21+ 1 more updateTty Biopharm Company Limited Proposes Dividend for the Period January 1, 2020 to December 31, 2020TTY Biopharm Company Limited at its board meeting held on March 19, 2021 proposed dividend for the period January 1, 2020 to December 31, 2020. The dividend proposed the total amount of cash dividends to shareholders TWD of 994,599,836. Per value of common stock to be TWD 10.
Reported Earnings • Mar 20Full year 2020 earnings released: EPS NT$3.72 (vs NT$3.62 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: NT$4.22b (down 5.5% from FY 2019). Net income: NT$924.2m (up 2.7% from FY 2019). Profit margin: 22% (up from 20% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
分析記事 • Mar 15Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?Today we will run through one way of estimating the intrinsic value of TTY Biopharm Company Limited ( GTSM:4105 ) by...
分析記事 • Feb 25Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?Could TTY Biopharm Company Limited ( GTSM:4105 ) be an attractive dividend share to own for the long haul? Investors...
Price Target Changed • Feb 19Price target lowered to NT$73.50Down from NT$79.14, the current price target is an average from 5 analysts. The new target price is 18% above the current share price of NT$62.30. As of last close, the stock is down 21% over the past year.
分析記事 • Feb 07TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?With its stock down 11% over the past three months, it is easy to disregard TTY Biopharm (GTSM:4105). However, stock...
お知らせ • Feb 06TTY Biopharm Company Limited, Annual General Meeting, Jun 09, 2021TTY Biopharm Company Limited, Annual General Meeting, Jun 09, 2021. Location: Building A, 2F., No. 19-10, Sanchong Rd., Nangang Dist. International Convention Center of Nangang Software Park Taipei City Taiwan Agenda: To consider the year 2020 business report; to consider the audit committee's review report on the year 2020 financial statements; to consider the report on employee and directors remuneration in year 2020; to consider the year 2020 business report and financial statements; to consider the year 2020 profit distribution; to consider the revising the policy of procedures for election of directors; to consider the release of non-competition restriction on new directors and its representatives; and to consider the other matters.
Is New 90 Day High Low • Jan 29New 90-day low: NT$61.40The company is down 19% from its price of NT$76.20 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is NT$118 per share.
分析記事 • Jan 19TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts SubstantiallyThe latest analyst coverage could presage a bad day for TTY Biopharm Company Limited ( GTSM:4105 ), with the analysts...
Is New 90 Day High Low • Jan 11New 90-day low: NT$68.10The company is down 19% from its price of NT$84.00 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is NT$251 per share.
分析記事 • Jan 10What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...
分析記事 • Dec 15TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Nov 25How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?Dividend paying stocks like TTY Biopharm Company Limited (GTSM:4105) tend to be popular with investors, and for good...
お知らせ • Nov 21TTY Biopharm Company Limited Announces Executive Changes, with Effect from January 20, 2021TTY Biopharm Company Limited replaced Tsai Shi-Hua with Hu Yu-Fang as research and development officer with effect from January 20, 2021.
Analyst Estimate Surprise Post Earnings • Nov 04Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 9.2%. Over the next year, revenue is forecast to grow 40%, compared to a 68% growth forecast for the Pharmaceuticals industry in Taiwan.
Reported Earnings • Nov 04Third quarter 2020 earnings released: EPS NT$0.89The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$1.02b (down 11% from 3Q 2019). Net income: NT$222.4m (down 30% from 3Q 2019). Profit margin: 22% (down from 28% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Oct 15Market bids up stock over the past weekAfter last week's 25% share price gain to NT$84.30, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 21.3x. This compares to an average P/E of 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders over the past three years are 5.3%.
Is New 90 Day High Low • Oct 15New 90-day high: NT$84.30The company is up 15% from its price of NT$73.20 on 17 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is NT$75.00 per share.
Major Estimate Revision • Oct 14Analysts lower revenue estimates to NT$4.14bThe 2020 consensus revenue estimate decreased from NT$4.64b. Earning per share (EPS) estimate was also lowered from NT$4.57 to NT$3.79 for the same period. Net income is expected to grow by 40% next year compared to 44% growth forecast for the Pharmaceuticals industry in Taiwan. The consensus price target increased from NT$78.66 to NT$80.17. Share price is up 13% to NT$76.40 over the past week.
Is New 90 Day High Low • Sep 24New 90-day low: NT$66.20The company is down 13% from its price of NT$76.20 on 24 June 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is NT$75.71 per share.
